Salivary Mitofusin-1 Levels in Periodontitis: Associations With Disease Severity, Smoking, and Treatment Response

Recruiting now · Not applicable

Conditions studied: Periodontal Disease, Chronic Periodontitis (Disorder)

In brief

Periodontitis (gum inflammation) is a common disease worldwide. This study aims to investigate a novel biomarker, a protein called Mitofusin-1 (Mfn1), in saliva that may be associated with the severity of periodontitis and response to treatment. The study will include periodontally healthy individuals, individuals with mild to severe periodontitis, and smokers with severe periodontitis. Participants will receive saliva samples and undergo clinical periodontal examinations. Individuals with periodontitis will receive standard periodontal treatment, and changes in Mfn1 levels will be assessed 3 months after treatment. The study is expected to shed light on the potential utility of Mfn1 as a marker in the diagnosis and follow-up of periodontitis.

Key facts

Study ID

NCT07262606

Run by

Ömer Faruk Okumuş

People needed

104

Starts

2025-11-01

Expected to finish

2026-11-01

Last updated by the study team

2025-12-03

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Willing and able to provide written informed consent.
• Systemically healthy (no history of diabetes mellitus, immunodeficiency, malignancy, or other systemic conditions that could affect periodontal status).
• Have a minimum of 20 natural teeth (excluding third molars).
• No antibiotic therapy or periodontal treatment in the last 6 months.
• For Healthy Control Group:
• No clinical attachment loss. Probing depth ≤ 3 mm. No radiographic evidence of bone loss. Low gingival and plaque index scores.
• For Mild Periodontitis Group:
• Diagnosed with Stage I or II periodontitis according to the 2018 AAP/EFP classification.
• Clinical attachment loss of 1-4 mm. Radiographic bone loss of ≤15-33%. Non-smoker.
• For Severe Periodontitis Group:
• Diagnosed with Stage III or IV periodontitis according to the 2018 AAP/EFP classification.
• Clinical attachment loss ≥ 5 mm. Radiographic bone loss to the mid-advanced level of the root. Non-smoker.
• For Severe Periodontitis with Smoking Group:
• Meets all criteria for the Severe Periodontitis Group. Regular smoker (at least 10 cigarettes per day for a minimum of 5 years).

You may not qualify if…

• Fewer than 20 natural teeth (excluding third molars).
• Presence of any systemic disease (e.g., diabetes mellitus, immunological disorders, cancer).
• Use of antibiotics or receiving periodontal treatment in the last 6 months.
• Pregnancy or lactation.
• For non-periodontitis groups (Healthy Control): Any signs of periodontitis.
• For periodontitis groups (all): History of smoking cessation for at least 5 years (must be either a current regular smoker or a never-smoker, depending on the group definition).

Where it is running

• Erzincan Binali Yıldırım University Faculty of Dentistry — Erzincan, Erzincan, Turkey (Türkiye) (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.